Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome

Haematologica

Volumn 89, Issue 5, 2004, Pages 619-620

  Ferrero, Dario ^a   Campa, Elisabetta ^a,b   Dellacasa, Chiara ^a   Campana, Silvia ^a,c   Foli, Cristina ^a,d   Boccadoro, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Ospedale Civile di Asti   (Italy)

^c Ospedale di Alba   (Italy)

^d Ospedale Evangelico Valdese   (Italy)

Author keywords

AML; Differentiating therapy; Myelodysplastic syndrome

Indexed keywords

ANTIBIOTIC AGENT; CALCITRIOL; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; ISOTRETINOIN; MERCAPTOPURINE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; DRUG FATALITY; DRUG RESPONSE; HEMATOPOIESIS; HUMAN; LEUKOCYTE COUNT; LIP DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; XEROSTOMIA;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITRIOL; CYTARABINE; DISEASE PROGRESSION; FEMALE; HUMANS; ISOTRETINOIN; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; THIOGUANINE;

EID: 2542466836     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Sekeres MA, Stone RM. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002;14:24-30.
2. Verbeek W, Ganser A. Evolving treatment options of myelodysplastic syndromes. Ann Hematol 2001;80:499-509.
3. Veneri D, Zanetti F, Franchini M, Ambrosetti A, Pizzolo G. Acute myeloid leukemia in the elderly: evaluation of overall survival in 69 consecutive patients. Haematologica 2002;87:447-8.
4. Ferrara F, Annunziata M, Copia C, Magrin S, Mele G, Mirto S. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica 1998;83:126-31.
5. Ferrero D, Carlesso N, Bresso P, Roux V, Pregno P, Gallo E, et al. Suppression of in vitro maintenance of non-promyelocytic myeloid leukemia clonogenic cells by all-trans retinoic acid: modulating effects of dihydroxylated vitamin D3, α interferon and "stem cell factor". Leuk Res 1997;21:51-8.
6. Tawhid H, Rees J. Triple combination of retinoic acid + 6-thioguanine + hexamethylene bisacetamide induces differentiation of human AML blasts in primary culture. Leuk Res 1990;14:109-17.
7. Ferrero D, Bruno B, Pregno P, Stefani S, Larizza E, Ciravegna G, et al. Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Leuk Res 1996;20:867-76.
8. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
9. Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 1992;65:162-8.
10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.